pamidronate disodium / Generic mfg. - LARVOL DELTA

Comparative efficacy of therapeutic interventions for thalassemia-induced osteoporosis: A network meta-analysis (ASH 2025) - "Compared with control, significant improvement in BMD at Total Hip or Femoral Neck (Z-score) was observed in Zoledronic Acid [MD = 0.51; 95% CI: 0.27 to 0.75], Alendronate [MD = 0.37; 95% CI: 0.20 to 0.54], Pamidronate [MD = 0.27; 95% CI: 0.01 to 0.54], and Zinc [MD = 0.26; 95% CI: 0.09 to 0.43]. It emphasizes the critical role of bisphosphonates, nutritional supplementation, and novel agents in enhancing bone health and overall quality of life for this patient population. These findings provide essential guidance for clinicians in optimizing osteoporosis management for individuals with thalassemia."

Retrospective data • Beta-Thalassemia • Genetic Disorders • Osteoporosis • Rheumatology

Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma (ASH 2025) - "Afterthe diagnosis of MM, 185 patients (85.6%) were prescribed BMA (75.1% zoledronate, 11.4% denosumaband 12.4% Pamidronate). Among patientswho received BMA, 17.8% developed SREs predominantly between two to five years after the first dose,which is comparable to previous studies. Future studies may look into initiatives to improve guidelineadherence."

Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases

Management of Neonatal Severe Hyperparathyroidism due to Homozygous CASR Mutation: Challenges and Literature Insights. (PubMed, Mol Syndromol) - "Despite initial treatment with hydration and furosemide, her hypercalcemia persisted. Cinacalcet was started but failed to control calcium levels, leading to the need for a subtotal parathyroidectomy at 2.5 months of age...Postoperatively, the patient developed hypocalcemia due to hungry bone syndrome and later experienced recurrent hypercalcemia, which was managed with pamidronate followed by calcitriol...Subtotal parathyroidectomy proved essential for controlling hypercalcemia. Continued documentation of NSHPT cases will help improve treatment strategies and outcomes for this rare condition."

Journal • Endocrine Disorders • Metabolic Disorders • CASR

Real-world outcomes comparing zoledronic acid and denosumab in patients with metastatic breast cancer and bone metastases: A propensity score matched analysis from a global federated health research network (SABCS 2025) - "Female patients aged 18 and above with breast cancer metastatic to the bone were identified and then stratified into two groups based on treatment with zoledronic acid or pamidronate. Our study revealed that patients with breast cancer with metastatic disease to the bone who received zoledronic acid had significantly lower rates of mortality but higher occurrence of osteoporotic fracture, hypercalcemia, and pathological fracture compared to those receiving denosumab. Additional longitudinal cohort studies are imperative to explore the outcomes between these agents and inform clinical practice guidelines in these patients."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Predictors of medication-related osteonecrosis of the jaw in HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors (SABCS 2025) - " A retrospective cohort of 193 female patients with HR+/HER2− mBC treated with CDK4/6i (ribociclib, palbociclib, abemaciclib) and ART (zoledronate, ibandronate, denosumab, clodronate and pamidronate) in the University Hospital Center Zagreb was analyzed with prior Ethics Committee approval. Older age and longer CDK4/6i exposure was associated with an increased risk of MRONJ in patients with HR+/HER2− mBC. Although MRONJ incidence appeared higher with abemaciclib and ribociclib compared to palbociclib, it did not reach statistical significance, possibly due to small numbers. These findings highlight the need for careful monitoring and risk assessment in patients undergoing long-term CDK4/6i therapy in combination with ART."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world outcomes comparing zoledronic acid and pamidronate in patients with metastatic breast cancer with bone metastases: A propensity score matched analysis from a global federated health research network (SABCS 2025) - "Our study revealed that patients with breast cancer with metastatic disease to the bone who received zoledronic acid had significantly lower rates of mortality, osteoporotic fracture, hypercalcemia, and pathological fracture compared to those receiving pamidronate. Additional longitudinal cohort studies are imperative to explore the outcomes between these agents and inform clinical practice guidelines."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Treatment responses and relapse predictors in pediatric CNO: insights from a referral center. (PubMed, Rheumatology (Oxford)) - "Conventional DMARDs are effective in a limited subset of CNO patients, who may represent a milder disease phenotype. The presence of skin involvement and a greater number of affected bones may both suggest a more aggressive disease course. Anti-TNF therapies are the most effective agents, while other biologics offer promising results in resistant cases. Prospective studies are needed to guide individualized treatment strategies."

Journal • Fatigue • Inflammation • Musculoskeletal Pain • Pain • Pediatrics

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy. (PubMed, JCO Oncol Pract) - "Bisphosphonates were equally efficacious in normalizing serum calcium in patients with HCM. Pamidronate 90 mg was not more efficacious than 60 mg. Rates of refractory hypocalcemia were similar."

Journal • Endocrine Disorders • Hematological Malignancies • Lung Cancer • Lymphoma • Metabolic Disorders • Multiple Myeloma • Oncology • Solid Tumor

Physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome: a cross-sectional study from China. (PubMed, Clin Rheumatol) - "While Whole body bone imaging and CT scans are widely used for the early diagnosis of adult SAPHO syndrome, there is a gap in the utilization of MRI and the practice of disease activity monitoring. Physicians prefer commonly used rheumatic drugs, but there remains limited application of bisphosphonates. Highlight • Our study first systematically investigated Chinese physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome. • We pointed out that the utilization of imaging tools (such as MRI) and bisphosphonates was low, suggesting that the diagnostic strategy needs to be optimized. • This study may aid the research of SAPHO syndrome at home and abroad, providing references."

Journal • Observational data • Dermatology • Musculoskeletal Diseases • Orthopedics • Rheumatology

Impact of Bone Modifying Agent Initiation Time, Frequency, and Duration on Skeletal-Related Events in Patients with Multiple Myeloma (ASH 2023) - "Bone modifying agents (BMA) such as denosumab or the bisphosphonates zoledronic acid and pamidronate, are used to inhibit osteoclast activity to prevent SREs. No significant association between time of BMA initiation, dosing frequency, or duration on development of SREs were observed. This suggests delaying the start time of BMAs to allow for dental clearance and initial treatment would not increase risk of SREs. Prospective trials are needed to confirm these findings."

Clinical • CNS Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics

Noncaseating Granulomatous Nephritis Presenting with Fanconi Syndrome (KIDNEY WEEK 2025) - "He was given Intravenous fluids and pamidronate with improvement in renal function and calcium...He was reponsive to prednisone treatment and his creatinine improved dramatically to 1.3 mg/dL. Discussion There are multiple causes of Fanconi syndrome but only 3 documented cases have been associated with sarcoidosis. The cause is thought to be from chronic interstitial nephritis leading to proximal tubular dysfunction."

Chronic Kidney Disease • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Hypotension • Immunology • Lymphoma • Metabolic Disorders • Nephrology • Renal Disease • Sarcoidosis

Recurrent Hypercalcemia in Chronic Lymphocytic Leukemia Without Transformation: A Diagnostic Trap (KIDNEY WEEK 2025) - "Case Description A 65-year-old male with relapsed CLL, CKD stage IV, and prior acalabrutinib use presented with symptomatic hypercalcemia (Ca 14.7 mg/dL) and acute kidney injury. Labs showed suppressed PTH, negative PTHrP, and high-normal vitamin D. Treated with IV fluids, pamidronate, and intranasal calcitonin...NM bone scan shows diffuse, symmetric radiotracer uptake in axial and appendicular skeleton, without focal lesions. Consistent with metabolic bone disease, not skeletal malignancy."

Acute Kidney Injury • Chronic Kidney Disease • Chronic Lymphocytic Leukemia • Endocrine Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease • Richter's Syndrome • Secondary Hyperparathyroidism

Beyond Averages: Informing Clinical Decision Making in the Pharmacologic Treatment of CRPS-1 using Bayesian Network Meta-Analysis (ASRA-FALL 2025) - "Across 17 trials, a total of 375 subjects were randomized to active treatment arms, and 379 to placebo. The evidence network was a placebo-anchored star (Figure 1), with edge thickness proportional to the number of trials per comparison. Treatments included: Neridronate: n=160 Ketamine: n=79 Alendronate: n=59 Pamidronate: n=48 Gabapentin: n=46 Corticosteroids: n=41 Mannitol: n=41 IVIG: n=13 Scavengers / Magnesium Sulfate: n=257 Ranked posterior probabilities of achieving a ≥20 mm VAS pain reduction, alongside average placebo-adjusted effects and 95% credible intervals, are summarized in Table 2."

Late-breaking abstract • Retrospective data • Musculoskeletal Pain

Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures (ACR Convergence 2025) - "Those with ESRD, metabolic bone diseases other than osteoporosis, cancer, a filled prescription for etidronate, pamidronate or tiludronate or those whose dose of zoledronic acid was or < 273 days from the initial dose were excluded. The adjusted average time to complication is shorter in patients with SFF compared to THF. However, the adjusted average time to complication in patients with AFF does not differ from those with THF."

Chronic Kidney Disease • Musculoskeletal Diseases • Orthopedics • Renal Disease • Rheumatology

MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ) FOLLOWING DENOSUMAB TREATMENT (CHEST 2025) - "Intravenous bisphosphonates (pamidronate and zoledronic acid) denosumab are approved for prevention of SRE's and are effective to reduce bone pain, hypercalcemia, and the risk of pathologic fractures. Patients taking medications for osteoporosis or malignancy need careful monitoring on its side effect. Medication Related Osteonecrosis of the Jaw (MRONJ) is rare but debilitating condition. The risk is considered dose-time dependent hence this can be managed by evaluating the route and the duration of administration."

Breast Cancer • CNS Disorders • Dental Disorders • Endocrine Disorders • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Infectious Disease • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • Periodontitis • Rheumatology • Solid Tumor • HER-2 • PGR

PSEUDOHYPERPHOSPHATEMIA IN A PATIENT WITH MULTIPLE MYELOMA (CHEST 2025) - "He was treated for anemia and hypercalcemia with 4 units PRBC, dexamethasone 40 mg IV daily, calcitonin 40 units, pamidronate 30 mg intravenous, normal saline 0.9% running at 100 ml/h. In our case, it is important to recognize pseudohyperphosphatemia in patients with plasma cell dyscrasias to avoid unnecessary interventions. Results were obscured by the patient's multiple myeloma (MM) which then prompted us to further evaluate hyperphosphatemia. Clinicians treating MM should be wary of the interference of paraproteins in the phosphate-measuring assays that can falsely elevate phosphorus levels."

Clinical • Anemia • Endocrine Disorders • Hematological Malignancies • Hepatology • Metabolic Disorders • Monoclonal Gammopathy • Multiple Myeloma • Nephrology • Oncology • Renal Disease

In Situ Remodeling of Tumor Microenvironment via Specific Cancer-Associated Fibroblasts Subtype Engineering to Boost Antitumor Immunity. (PubMed, ACS Nano) - "We specifically engineer these CAFs in situ to enhance antitumor immunity using an innovative nanodrug, IL-15 plasmid-loaded FAP-sensitive MgCa/z-Gly-Pro-pamidronate acid nanoparticles (PN/MCG NPs)...Furthermore, we also prove that FAP+ αSMA+ human mammary fibroblast cells (FAP+ αSMA+ HMFs) also can be engineered by PN/MCG NPs in vitro. Our findings demonstrate that in situ CAF engineering is a promising strategy to remodel the tumor microenvironment and enhance immunotherapy in TNBC."

Biomarker • IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CAFs • IL15

Chronic Non-Bacterial Osteomyelitis of the Petrous Bone: A Case Series (ACR Convergence 2025) - "All patients were treated with a non-steroidal anti-inflammatory drug (NSAID) and the one patient with hearing loss also received anti-TNF therapy (adalimumab) and responded well with resolution of hearing loss...Consensus guidelines provide options including non-steroidal anti-inflammatories (first line), glucocorticoids, disease modifying drugs (methotrexate, sulfasalazine), Tumor Necrosis Factor (TNF) inhibitors with or without methotrexate, and bisphosphates (pamidronate or zolendronic acid)... The skull is rarely involved in CNO, with ~1% of patients presenting with lesions in the frontal bone. Temporal bone involvement has rarely been reported with only two cases to our knowledge . It is unknown why CNO rarely affects the skull."

Clinical • CNS Disorders • Inflammation • Orthopedics • Otorhinolaryngology

Assessment of Bone Density in Osteogenesis Imperfecta in Pediatric and Adolescent Age Group: Can the Metacarpal Index Play a Role? (PubMed, Indian J Orthop) - "The change in MCI after pamidronate therapy was monitored, and those who were initiated on pamidronate at a younger age showed more improvement in MCI than those who were started at a later age. Our study suggests that when DXA measurements are not feasible, MCI can be a potential tool to assess bone quality and evaluate bisphosphonate therapy in the OI population."

Journal • Genetic Disorders • Pediatrics

Host Immunomodulatory Interventions in Severe Influenza. (PubMed, J Infect Dis) - "The World Health Organization conditionally advises against the use of systemic corticosteroids, macrolides, plasma therapy, mechanistic target of rapamycin inhibitors, and nonsteroidal anti-inflammatory drugs for such patients...An open-label randomized controlled trial (RCT) found that a triple combination of oseltamivir, clarithromycin, and naproxen improved outcomes in severe influenza...In contrast, adding macrolides or nitazoxanide has not consistently improved clinical outcomes. Promising evidence exists for anti-C5a antibodies in COVID-19, while case reports hint that intravenous N-acetylcysteine may benefit severe influenza pneumonia...Mycophenolic acid, pamidronate, and peroxisome proliferator-activated receptor gamma agonists are low priorities due to toxicity concerns...Treatment of severe influenza requires a multidisciplinary approach that integrates antiviral and immunomodulatory strategies. Clarifying these roles may enhance patient outcomes."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • mTOR

Identification of Drugs Associated With Oral Ulcers Based on Pharmacovigilance. (PubMed, Int Dent J) - "This study systematically identified approximately 289 drugs significantly associated with oral ulcer risk, including immunosuppressants, cardiovascular drugs and bronchodilators. Based on pharmacovigilance signal detection and regression analysis, patients on long-term treatment with these drugs should receive enhanced oral monitoring. As this is an observational study, further prospective and experimental research is needed to confirm causality."

Adverse events • Journal • Cardiovascular • Pain

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific advisory group of Australia (MSAG) to myeloma australia. (PubMed, Expert Rev Hematol) - "Traditionally, bisphosphonates such as zoledronic acid and pamidronate, have been used in the prophylaxis and treatment of myeloma bone disease (MBD)...This updated guideline recommends a two-year course of bisphosphonates treatment, with suggested extension of dosing intervals if the disease remains stable.Denosumab, a monoclonal antibody targeting receptor activator of nuclear factor **B ligand (RANKL), has demonstrated efficacy and non-inferiority compared to zoledronic acid in the treatment of MBD and may serve as an alternative treatment option especially with renal impairment. Further research into the utility of bone turnover markers for guiding anti-resorptive therapy in myeloma bone disease may provide significant clinical benefit. In addition, therapeutic strategies aimed at enhancing osteoblastic activity represent a potential therapeutic strategy."

Clinical • Journal • Review • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics • Renal Disease

Clinical, Bone Mineral Density and Spinal Remodelling Responses to Zoledronate Treatment in Chronic Recurrent Multifocal Osteomyelitis. (PubMed, Diagnostics (Basel)) - "The American College of Rheumatology Consensus Guidelines suggest considering bisphosphonates in a certain category of patients based on evidence from a handful of case series reporting the outcome of pamidronate use...This correlated to the complete treatment de-escalation of opioids (n = 3/3; 1 was excluded as they had not yet started treatment), steroids (n = 8/8) and methotrexate (n = 2/2)...Spinal remodelling is minimal in vertebra plana lesions. Bone density monitoring and personalisation of the bisphosphonate dose and regimen are strongly recommended to avoid overtreatment."

Journal • Inflammation • Musculoskeletal Diseases • Orthopedics • Pain • Rheumatology

A rare case of McCune-Albright syndrome in a young male with hyperthyroidism and hypertrophic scars. (PubMed, Oxf Med Case Reports) - "His condition was initially misdiagnosed as osteogenesis imperfecta but the finding of hyperthyroidism reaffirms the diagnosis of MAS. He was treated with pamidronate, carbimazole and surgical operations to correct bony deformities."

Journal • Endocrine Disorders • Genetic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • GNAS